Related Experiment Video

Updated: Nov 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis

Hai-Long Zhang1, Yiqian Li2

  • 1Central International Intellectual Property (Baotou) Co., Ltd., Baotou, Inner Mongolia 014030, China.

Recent Patents on Anti-Cancer Drug Discovery
|April 13, 2021
PubMed
Abstract

Insights

Large pharmaceutical companies dominate intellectual property for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) targeted cancer therapies. Research shows EGFR remains an attractive target, with small molecule inhibitors leading patent filings.

Area of Science:

  • Oncology
  • Pharmaceutical Research
  • Intellectual Property Analysis

Background:

  • Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are crucial in cancer development.
  • Targeted therapies offer advantages over traditional chemotherapy for cancer treatment.
  • EGFR and ALK are significant targets for novel drug development.

Purpose of the Study:

  • To analyze recent trends in research and development (R&D) for EGFR and ALK targets.
  • To understand the intellectual property landscape surrounding EGFR and ALK targets.

Main Methods:

  • Comprehensive US patent analysis of EGFR-based and ALK-based targets.
  • Data collection spanned from September 2001 to September 2020.

Main Results:

  • Key technologies for EGFR/ALK targets are primarily developed by major global pharmaceutical firms and US entities.
  • Small molecule inhibitors represent a significant portion of patents for EGFR-based targets.
  • Recent FDA-approved small molecule targeted drugs were identified.

Conclusions:

  • Global pharmaceutical giants and US academic/corporate institutions lead in targeted drug R&D.
  • EGFR continues to be a highly pursued target for cancer research and drug development.
  • Leading pharmaceutical companies favor independent innovation over collaborations for key technology development.
Keywords:
ALKEGFRanaplastic lymphoma kinase.epidermal growth factor receptorpatent analysistargeted drugs

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K